GILEAD SCIENCES INC (GILD)       62.63  +0.29 (+0.47%)

62.63  +0.29 (+0.47%)

US3755581036 - Common Stock - After market: 62.63 0 (0%)


Fundamental Rating

5

Overall GILD gets a fundamental rating of 5 out of 10. We evaluated GILD against 637 industry peers in the Biotechnology industry. While GILD has a great profitability rating, there are some minor concerns on its financial health. GILD has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

7

GILD's Return On Assets of 6.58% is amongst the best returns of the industry. GILD outperforms 94% of its industry peers. The industry average Return On Assets is -41.27%.
GILD's Profit Margin of 15.04% is amongst the best returns of the industry. GILD outperforms 90% of its industry peers. The industry average Profit Margin is -408.39%.

GILD has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for GILD.
GILD's Return On Equity of 20.44% is in line with the rest of the industry. The industry average Return On Equity is 20.55%.
VS Industry

ROA (6.58%) VS Industry: 94% outperformed.

-1,441.42
115.38

ROE (20.44%) VS Industry: 47% outperformed.

0.23
535.19

Profit Margin (15.04%) VS Industry: 90% outperformed.

-1,173,705.71
8,610.80

Valuation

Valuation Rating

3

The Price/Earnings Ratio is 8.90, which indicates a very decent valuation of GILD.
Compared to an average industry Price/Earning Ratio of 12.02, GILD is valued a bit cheaper than its industry peers.
With a Forward Price/Earnings Ratio of 9.49, the valuation of GILD can be described as very reasonable.

When comparing the current price to the book value of GILD, we can conclude it is valued correctly. It is trading at 3.88 times its book value.
When comparing the price book ratio of GILD to the average industry price book ratio of 1.60, GILD is valued more expensive than its industry peers. 81% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 0.85, GILD is valued more expensive than its industry peers. 88% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (8.9) VS Industry: 66% outperformed.

194.92
0.16

Price/Book (3.88) VS Industry: 19% outperformed.

169.10
0.08

Enterprise Value/ EBITDA (8.41) VS Industry: 12% outperformed.

4,208.87
0.01

Growth

Growth Rating

3

When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
GILD shows a decrease in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -8.81% yearly.
The Earnings Per Share is expected to grow by 0.10% on average over the next 5 years.

Looking at the last year, GILD shows a small growth in Revenue. The Revenue has grown by 3.29% in the last year.
GILD shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -2.12% yearly.
GILD is expected to show a decrease in Revenue. In the coming 5 years, the Revenue will decrease by -1.11% yearly.
GILD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.67%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-8.81% 3.01% -14.67% -6.85% -4.84% -0.81% 0.1%
Revenue-2.12% 7.26% 3.29% -5.35% -3.77% -1.51% -1.11%

Health

Health Rating

4

The Altman-Z score of GILD is much better than the industry average of -0.10.
GILD has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for GILD.
GILD has a Current Ratio of 1.43. This is a normal value and indicates that GILD is financially healthy and should not expect problems in meeting its short term obligations.
GILD has a Quick Ratio of 1.27. This is a normal value and indicates that GILD is financially healthy and should not expect problems in meeting its short term obligations.

An Altman-Z score of 2.33 indicates that GILD is not a great score, but indicates only limited risk for bankruptcy at the moment.
When comparing the Current Ratio of GILD to the average industry Current Ratio of 6.52, GILD is less able to pay its short term obligations than its industry peers. 92% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.47, GILD is worse placed to pay its short term obligations than its industry peers. 92% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, GILD is requires more financing than its industry peers. 96% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (1.25) VS Industry: 4% outperformed.

18.24
0.00

Quick Ratio (1.27) VS Industry: 8% outperformed.

0.03
399.16

Current Ratio (1.43) VS Industry: 8% outperformed.

0.08
401.12

Altman-Z (2.33) VS Industry: 64% outperformed.

-1,821.48
293.92

Dividend

Dividend Rating

7

With a Yearly Dividend Yield of 4.45%, GILD is a good candidate for dividend investing.
GILD's Dividend Yield is rather good when compared to the industry average which is at 3.92. GILD pays more dividend than 100% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.48, GILD pays a better dividend.
On average, the dividend of GILD grows each year by 7.60%, which is quite nice.

GILD has been paying a dividend for over 5 years, so it has already some track record.
The Dividend Rate of GILD has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
88.45% of the earnings are spent on dividend by GILD. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (4.45%) VS Industry: 100% outperformed.

3.12
4.45
GILD Daily chart

GILEAD SCIENCES INC62.63

NASDAQ:GILD (9/27/2022, 7:00:01 PM)+0.29 (+0.47%)

After market: 62.63 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-02 2022-08-02/amc Earnings (Next) 10-26 2022-10-26
Ins Owners 0.04% Inst Owners 79.25%
Market Cap 78.50B Analysts 70.81
Valuation
PE 8.9 Fwd PE 9.49
PEG (NY) N/A PEG (5Y) N/A
P/S 2.85 P/B 3.88
EV/EBITDA 8.41
Dividend
Dividend Yield 4.45% Dividend Growth 7.6%
DP 88.45% Ex-Date 09-14 2022-09-14 (0.73)
Growth
EPS 1Y -14.67% EPS 3Y 3.01%
EPS 5Y -8.81% EPS growth Q2Q -15.51%
EPS Next Y -6.85% EPS Next 2Y -4.84%
EPS Next 3Y -0.81% EPS Next 5Y 0.1%
Revenue growth 1Y 3.29% Revenue growth 3Y 7.26%
Revenue growth 5Y -2.12% Revenue growth Q2Q 0.69%
Revenue Next Year -5.35% Revenue Next 2Y -3.77%
Revenue Next 3Y -1.51% Revenue Next 5Y -1.11%
Health
Current Ratio 1.43 Quick Ratio 1.27
Altman-Z 2.33 F-Score 7
Debt/Equity 1.25
Profitability
ROA 6.58% ROE 20.44%
ROIC 49.64% ROICg 14.3%
PM 15.04 OM 35.28
Asset Turnover 0.44

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA